Orbicular Announces Health Canada Approval for a g-Ozempic (Semaglutide Injection) in Partnership with Apotex
* Generic Semaglutide Injection developed by Orbicular receives Notice of Compliance from Health Canada — our second G-7 Approval by stringent regulatory authority (SRA) to greenlight the program after the U.S. FDA's Tentative Approval * A fully indigenous Indian innovation: API, pen device, formulation, manufacturing and analytical technology developed end-to-end within India Orbicular Pharmaceutical Technologies Pvt. Ltd., a specialty pharmaceutical…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
 in Partnership with Apotex * Generic Semaglutide Injection developed by){kind=link}